Pharmaceutical Companies Vaccines White Paper 
Pharmaceutical Technology
FEBRUARY 1, 2023
RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ISPE
JANUARY 3, 2023
A landmark project for a major international pharmaceutical company was the starting point for a series of follow-up projects in Switzerland and Germany. . Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities.
Pharmaceutical Technology
MARCH 22, 2023
In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. The European Commission plans to launch its revised EU pharmaceutical package in Q1 2023 to ease drug shortages,” she says.
Pharmaceutical Technology
DECEMBER 15, 2022
The Singapore Government has launched Biologics Pharma Innovation Programme Singapore (BioPIPS), which aims to increase the country’s manufacturing capacity for biologics, including recombinant proteins and vaccines. The organizations plan to use data analytics to improve manufacturing processes. Additionally, Merck & Co.
Pharmaceutical Technology
MARCH 22, 2023
During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry. While production volumes have now fallen, future vaccine demand is hard to predict, as booster shots could be needed at any point to control emerging variants.
Pharmaceutical Technology
JANUARY 25, 2023
The global vaccine rollout would never have taken place without the advances in visibility and control over supply chains that it necessitated. Shoring these up will be a prerequisite for ushering in the age of decentralised pharmaceuticals. But it also ramped up adoption of decentralisation by highlighting its value.
Expert insights. Personalized for you.
64 
Let's personalize your content